The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
Open accessAbstract
The phosphoinositide 3-kinase (PI3K) pathway plays an integral role in many cellular processes and is frequently altered in cancer, contributing to tumor growth and survival. Small molecule inhibitors have been developed that target the three major nodes of this pathway: PI3K, AKT, and mammalian target of rapamycin. However, because oncogenic PI3K pathway activation is achieved in diverse, potentially redundant ways, the clinical efficacy of these inhibitors as monotherapies has, so far, been limited, despite demonstrating promising preclinical activity. Moreover, pathway activation is associated with resistance to other therapies; thus, in combination, PI3K pathway inhibitors could restore therapeutic sensitivity to these agents. To maximize therapeutic benefit, drug combinations and schedules must be explored to identify those with the highest efficacy and lowest toxicity overlap. In addition, defining appropriate patient subpopulations, for both monotherapy and drug combinations, will be important. However, identifying predictive biomarkers remains a challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“PI3K pathway alterations occur in 50% of glioblastoma multiforme (GBM) tumors and are associated with poor survival.(27) Mutations in PTEN occur in 5% to 40% of GBM tumors, whereas loss of heterozygosity occurs in 60% to 80% of all cases.”
BackgroundComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Targeting PI3K/mTOR Signaling in Cancer
Arcaro, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00084 · Cited by 1,024
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982
Folkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 741
Lannutti, B. J., Meadows, S. A., Herman, S. E. M., Kashishian, A., Steiner, B., Johnson, A. J., Byrd, J. C., Tyner, J. W., Loriaux, M. M., Deininger, M., et al. (2011) · Blood · doi:10.1182/blood-2010-03-275305 · Cited by 720
The therapeutic promise of the cancer stem cell concept
Frank, N. Y., Schatton, T., & Frank, M. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41004 · Cited by 636
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
Lui, V. W. Y., Hedberg, M. L., Li, H., Vangara, B. S., Pendleton, K., Zeng, Y., Lu, Y., Zhang, Q., Du, Y., Gilbert, B. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0103 · Cited by 589
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
ErbB receptors: from oncogenes to targeted cancer therapies
Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., & Greene, M. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32278 · Cited by 574
Yap, T. A., Yan, L., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K., Baird, R. D., Delgado, L., Taylor, A., Lupinacci, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5263 · Cited by 539
Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 529
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524
Yardley, D. A., Noguchi, S., Pritchard, K. I., Burris, H. A., Baselga, J., Gnant, M., Hortobagyi, G. N., Campone, M., Pistilli, B., Piccart, M., et al. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0060-1 · Cited by 522
Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 501
Therapy-induced tumour secretomes promote resistance and tumour progression
Obenauf, A. C., Zou, Y., Ji, A. L., Vanharanta, S., Shu, W., Shi, H., Kong, X., Bosenberg, M. C., Wiesner, T., Rosen, N., et al. (2015) · Nature · doi:10.1038/nature14336 · Cited by 494
Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0824-t · Cited by 471
Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 465
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Dienstmann, R., Rodon, J., Serra, V., & Tabernero, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0639 · Cited by 462
Gewinner, C., Wang, Z. C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., Barretina, J., Lin, W. M., Rameh, L., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 461
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4765 · Cited by 455
Dissecting the role of mTOR: Lessons from mTOR inhibitors
Dowling, R. J. O., Topisirovic, I., Fonseca, B. D., & Sonenberg, N. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.001 · Cited by 454
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M., & Knight, Z. A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.117 · Cited by 440
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Burris, H. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2043-3 · Cited by 440
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J. J., Spratt, D. E., Viola-Villegas, N. T., Castel, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4442 · Cited by 432
Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431
Tumour heterogeneity and the evolution of polyclonal drug resistance
Burrell, R. A., & Swanton, C. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.005 · Cited by 417
deGraffenried, L. A., Friedrichs, W. E., Russell, D. H., Donzis, E. J., Middleton, A. K., Silva, J. M., Roth, R. A., & Hidalgo, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0035 · Cited by 387
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Muranen, T., Selfors, L. M., Worster, D. T., Iwanicki, M. P., Song, L., Morales, F. C., Gao, S., Mills, G. B., & Brugge, J. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.024 · Cited by 384
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
Knight, S. D., Adams, N. D., Burgess, J. L., Chaudhari, A. M., Darcy, M. G., Donatelli, C. A., Luengo, J. I., Newlander, K. A., Parrish, C. A., Ridgers, L. H., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml900028r · Cited by 373
Banerjee, S., & Kaye, S. B. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2243 · Cited by 357
Akt-regulated pathways in prostate cancer
Majumder, P. K., & Sellers, W. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209096 · Cited by 344
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005747 · Cited by 332
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Janku, F., Tsimberidou, A. M., Garrido-Laguna, I., Wang, X., Luthra, R., Hong, D. S., Naing, A., Falchook, G. S., Moroney, J. W., Piha-Paul, S. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0994 · Cited by 331
Strategies for the management of adverse events associated with mTOR inhibitors
Kaplan, B., Qazi, Y., & Wellen, J. R. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2014.03.002 · Cited by 322
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
Bitting, R. L., & Armstrong, A. J. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-12-0394 · Cited by 311
Molecular biology of lung cancer.
Cooper, W. A., Lam, D. C.-L., O'Toole, S. A., & Minna, J. D. (2013) · PubMed · doi:10.3978/j.issn.2072-1439.2013.08.03 · Cited by 303
Janku, F., Wheler, J. J., Naing, A., Falchook, G. S., Hong, D. S., Stepanek, V. M., Fu, S., Piha-Paul, S. A., Lee, J. J., Luthra, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1726 · Cited by 300
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
Hsieh, A., & Edlind, M. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122876 · Cited by 276
Sun, T., Aceto, N., Meerbrey, K. L., Kessler, J. D., Zhou, C., Migliaccio, I., Nguyen, D. X., Pavlova, N. N., Botero, M., Huang, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.02.003 · Cited by 276
Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer
Baselga, J. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-12 · Cited by 261
Liu, N., Rowley, B. R., Bull, C. O., Schneider, C., Haegebarth, A., Schatz, C. A., Fracasso, P. R., Wilkie, D. P., Hentemann, M., Wilhelm, S. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0993-t · Cited by 258
Kahl, B. S., Spurgeon, S. E., Furman, R. R., Flinn, I. W., Coutre, S. E., Brown, J. R., Benson, D. M., Byrd, J. C., Peterman, S., Cho, Y., et al. (2014) · Blood · doi:10.1182/blood-2013-11-537555 · Cited by 252
Schwartz, S., Wongvipat, J., Trigwell, C. B., Hancox, U., Carver, B. S., Rodrik-Outmezguine, V., Will, M., Yellen, P., de Stanchina, E., Baselga, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.008 · Cited by 246
Marsit, C. J., Zheng, S., Aldape, K., Hinds, P. W., Nelson, H. H., Wiencke, J. K., & Kelsey, K. T. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.05.006 · Cited by 243
Majewski, I. J., Nuciforo, P., Mittempergher, L., Bosma, A. J., Eidtmann, H., Holmes, E., Sotiriou, C., Fumagalli, D., Jimenez, J., Aura, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2158 · Cited by 235
Busaidy, N. L., Farooki, A., Dowlati, A., Perentesis, J. P., Dancey, J. E., Doyle, L. A., Brell, J. M., & Siu, L. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7356 · Cited by 231
Perifosine: Update on a novel Akt inhibitor
Gills, J. J., & Dennis, P. A. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0016-4 · Cited by 221
Sutherlin, D. P., Bao, L., Berry, M., Castanedo, G., Chuckowree, I., Dotson, J., Folks, A., Friedman, L., Goldsmith, R., Gunzner, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2009327 · Cited by 219
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Britten, C. D. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2121-1 · Cited by 216
Ilic, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 211
Pike, K. G., Malagu, K., Hummersone, M. G., Menear, K. A., Duggan, H. M. E., Gomez, S., Martin, N. M. B., Ruston, L., Pass, S. L., & Pass, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.019 · Cited by 207
Costa, C., Ebi, H., Martini, M., Beausoleil, S. A., Faber, A. C., Jakubik, C. T., Huang, A., Wang, Y., Nishtala, M., Hall, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.007 · Cited by 203
Averous, J., Fonseca, B. D., & Proud, C. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210715 · Cited by 194
Malanga, D., Scrima, M., De Marco, C., Fabiani, F., De Rosa, N., de Gisi, S., Malara, N., Savino, R., Rocco, G., Chiappetta, G., et al. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5485 · Cited by 190
Rodon, J., Braña, I., Siu, L. L., De Jonge, M. J., Homji, N., Mills, D., Di Tomaso, E., Sarr, C., Trandafir, L., Massacesi, C., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0082-9 · Cited by 186
Sanchez, C. G., Ma, C. X., Crowder, R. J., Guintoli, T., Phommaly, C., Gao, F., Lin, L., & Ellis, M. J. (2011) · Breast Cancer Research · doi:10.1186/bcr2833 · Cited by 184
Molife, L. R., Yan, L., Vitfell-Rasmussen, J., Zernhelt, A. M., Sullivan, D. M., Cassier, P. A., Chen, E., Biondo, A., Tetteh, E., Siu, L. L., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-1 · Cited by 183
Takuwa, N., Fukui, Y., & Takuwa, Y. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1346 · Cited by 182
Ndubaku, C. O., Heffron, T. P., Staben, S. T., Baumgardner, M., Blaquiere, N., Bradley, E., Bull, R., Do, S., Dotson, J., Dudley, D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4003632 · Cited by 179
Broek, R. V., Mohan, S., Eytan, D. F., Chen, Z., & Waes, C. V. (2013) · Oral Diseases · doi:10.1111/odi.12206 · Cited by 177
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
Mallon, R., Feldberg, L. R., Lucas, J., Chaudhary, I., Dehnhardt, C., Santos, E. D., Chen, Z., dos Santos, O., Ayral-Kaloustian, S., Venkatesan, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1694 · Cited by 172
Bellmunt, J., Szczylik, C., Feingold, J., Strahs, A., & Berkenblit, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn066 · Cited by 170
PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
Yuan, J., Mehta, P. P., Yin, M.-J., Sun, S., Zou, A., Chen, J., Rafidi, K., Feng, Z., Nickel, J., Engebretsen, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0185 · Cited by 163
Markman, B., Tabernero, J. M., Krop, I. E., Shapiro, G. I., Siu, L. L., Chen, L. C., Mita, M. M., Cuero, M. M., Stutvoet, S., Birle, D. C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds011 · Cited by 158
Opel, D., Westhoff, M., Bender, A., Braun, V., Debatin, K., & Fulda, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6769 · Cited by 155
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Serra, V., Eichhorn, P. J. A., García-García, C., Ibrahim, Y. H., Prudkin, L., Sánchez, G., Rodríguez, O., Antón, P., Parra, J.-L., Marlow, S., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66343 · Cited by 154
Ihle, N. T., Paine-Murrieta, G. D., Berggren, M. I., Baker, A. F., Tate, W. R., Wipf, P., Abraham, R. T., Kirkpatrick, D. L., & Powis, G. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0149 · Cited by 154
Shapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1777 · Cited by 152
Decreased Expression and Androgen Regulation of the Tumor Suppressor Gene INPP4B in Prostate Cancer
Hodgson, M. C., Shao, L.-J., Frolov, A., Li, R., Peterson, L. E., Ayala, G., Ittmann, M., Weigel, N. L., & Agoulnik, I. U. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2314 · Cited by 152
Chemical modification of rapamycin: the discovery of SDZ RAD
Sedrani, R. C., Cottens, S., Kallen, J. A., & Schüler, W. (1998) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)00587-9 · Cited by 147
Fokas, E., Im, J. H., Hill, S. A., Yameen, S., Stratford, M. R. L., Beech, J. S., Hackl, W., Maira, S.-M., Bernhard, E. J., McKenna, W. G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2263 · Cited by 145
Spencer, A., Yoon, S.-S., Harrison, S. J., Morris, S. R., Smith, D. A., Brigandi, R. A., Gauvin, J., Kumar, R., Opalinska, J. B., & Chen, C. (2014) · Blood · doi:10.1182/blood-2014-03-559963 · Cited by 142
Early Involvement of the Phosphatidylinositol 3-Kinase/Akt Pathway in Lung Cancer Progression
Massion, P. P., Taflan, P. M., Shyr, Y., Rahman, S. M. J., Yildiz, P., Shakthour, B., Edgerton, M. E., Ninan, M., Andersen, J. J., & Gonzalez, A. L. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-487oc · Cited by 141
PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines
Weigelt, B., Warne, P. H., Lambros, M. B. K., Reis-Filho, J. S., & Downward, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3815 · Cited by 140
The Biological Role of PI3K Pathway in Lung Cancer
Sarris, E., Saif, M. W., & Syrigos, K. (2012) · Pharmaceuticals · doi:10.3390/ph5111236 · Cited by 136
Edwards, S. R., & Wandless, T. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700498200 · Cited by 134
Shor, B., Zhang, W., Toral‐Barza, L., Lucas, J., Abraham, R. T., Gibbons, J. J., & Yu, K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6487 · Cited by 131
Targeting PI3K Signaling as a Therapeutic Approach for Colorectal Cancer
Zhang, J., Roberts, T. M., & Shivdasani, R. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.010 · Cited by 130
Weber, G. L., Parat, M., Binder, Z. A., Gallia, G. L., & Riggins, G. J. (2011) · Oncotarget · doi:10.18632/oncotarget.346 · Cited by 114
Rivera, V. M., Squillace, R. M., Miller, D., Berk, L., Wardwell, S., Ning, Y., Pollock, R. M., Narasimhan, N. I., Iuliucci, J. D., Wang, F., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0792 · Cited by 114
Albiges, L. K., Chamming’s, F., Duclos, B., Stern, M., Motzer, R. J., Ravaud, A., & Camus, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds115 · Cited by 113
Marques, R. B., Aghai, A., de Ridder, C. M. A., Stuurman, D. C., Hoeben, S. A. H., Boer, A., Ellston, R. P. A., Barry, S. T., Davies, B. R., Trapman, J., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.08.053 · Cited by 108
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
Gonzalez-Angulo, A. M., & Blumenschein, G. R. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.11.002 · Cited by 108
Tanaka, H., Yoshida, M., Tanimura, H., Fujii, T., Sakata, K., Tachibana, Y., Ohwada, J., Ebiike, H., Kuramoto, S., Morita, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2882 · Cited by 108
INPP4B: the New Kid on the PI3K Block
Agoulnik, I. U., Hodgson, M. C., Bowden, W. A., & Ittmann, M. (2011) · Oncotarget · doi:10.18632/oncotarget.260 · Cited by 106
Falcón, B. L., Barr, S. M., Gokhale, P. C., Chou, J., Fogarty, J., Depeille, P., Miglarese, M. R., Epstein, D. M., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3126 · Cited by 103
Bender, A., Opel, D., Naumann, I., Kappler, R., Friedman, L. S., von Schweinitz, D., Debatin, K., & Fulda, S. (2010) · Oncogene · doi:10.1038/onc.2010.429 · Cited by 100
Papadopoulos, K. P., Tabernero, J. M., Markman, B., Patnaik, A., Tolcher, A. W., Baselga, J. M., Shi, W., Égile, C., Ruiz-Soto, R., Laird, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2403 · Cited by 99
Self-citationEren, M. K., Boylu, T., & Tabor, V. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-36 · Cited by 97
The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
Carden, C. P., Stewart, A., Thavasu, P., Kipps, E., Pope, L., Crespo, M., Miranda, S., Attard, G., Garrett, M. D., Clarke, P. A., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0996 · Cited by 96
Hartford, C. M., Desai, A. A., Janisch, L. A., Karrison, T. G., Rivera, V. M., Berk, L., Loewy, J. W., Kindler, H. L., Stadler, W. M., Knowles, H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2076 · Cited by 96
Ando, Y., Inada‐Inoue, M., Mitsuma, A., Yoshino, T., Ohtsu, A., Suenaga, N., Sato, M., Kakizume, T., Robson, M., Quadt, C., et al. (2014) · Cancer Science · doi:10.1111/cas.12350 · Cited by 88
Gonzalez-Angulo, A. M., Meric‐Bernstam, F., Chawla, S. P., Falchook, G. S., Hong, D. S., Akçakanat, A., Chen, H., Naing, A., Fu, S., Wheler, J. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3110 · Cited by 82
Britten, C. D., Adjei, A. A., Millham, R., Houk, B. E., Borzillo, G. V., Pierce, K. J., Wainberg, Z. A., & LoRusso, P. M. (2014) · Investigational New Drugs · doi:10.1007/s10637-013-0062-5 · Cited by 79
Self-citationBerenjeno, I. M., Guillermet‐Guibert, J., Pearce, W. P., Gray, A., Fleming, S., & Vanhaesebroeck, B. (2011) · Biochemical Journal · doi:10.1042/bj20111741 · Cited by 73
Carico, C., Nuño, M., Mukherjee, D. R., Elramsisy, A., Dantis, J., Hu, J. L., Rudnick, J. D., Yu, J. S., Black, K. L., Bannykh, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033684 · Cited by 71
Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function*
So, L., Yea, S. S., Oak, J. S., Lu, M., Manmadhan, A., Ke, Q. H., Janes, M. R., Kessler, L. V., Kucharski, J. M., Li, L., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.379446 · Cited by 68
PI3 kinase inhibitors in the clinic: an update.
Kurtz, J., & Ray-Coquard, I. L. (2012) · PubMed · Cited by 64
Tolcher, A. W., Goldman, J., Patnaik, A., Papadopoulos, K. P., Westwood, P., Kelly, C. S., Bumgardner, W., Sams, L. L., Geeganage, S., Wang, T., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.039 · Cited by 62
Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics: from Concept to Patient
Doroshow, J. H., & Parchment, R. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4562 · Cited by 62
Stjernström, A., Karlsson, C., Fernandez, O. J., Söderkvist, P., Karlsson, M. G., & Thunell, L. K. (2014) · Cancer Medicine · doi:10.1002/cam4.191 · Cited by 47
Lanasa, M. C., Glenn, M. J., Mato, A. R., et al. (2013) · Blood · doi:10.1182/blood.v122.21.678.678 · Cited by 41
Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor
Li, Y. (2009) · Cancer Research · Cited by 40
Absence of AKT1 Mutations in Glioblastoma
Bleeker, F. E., Lamba, S., Zanon, C., van Tilborg, A. A., Leenstra, S., Troost, D., Hulsebos, T. J. M., Vandertop, W. P., & Bardelli, A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005638 · Cited by 32
Akt signaling is required for glioblastoma maintenance in vivo.
Robinson, J. P., VanBrocklin, M. W., McKinney, A. J., Gach, H. M., & Holmen, S. L. (2011) · Europe PMC (PubMed Central) · Cited by 30
Shanmugam, V., Ramanathan, R. K., Lavender, N., Sinari, S. A., Chadha, M. K., Liang, W. S., Kurdoglu, A. A., Izatt, T., Christoforides, A., Benson, H., et al. (2014) · BMC Medical Genomics · doi:10.1186/1755-8794-7-36 · Cited by 21
Wu, M.-Q., Hu, P., Gao, J., Wei, W.-D., Xiao, X.-S., Tang, H., Li, X., Ge, Q.-D., Jia, W.-H., Liu, R.-B., et al. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.1.287 · Cited by 20
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition
Edgar, K. A., Crocker, L., Cheng, E., Wagle, M.-C., Wongchenko, M. J., Yan, Y., Wilson, T. R., Dompe, N., Neve, R. M., Belvin, M. P., et al. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.10 · Cited by 15
Wen, P. Y., Wen, P. Y., Yung, W. K. A., Mellinghoff, I. K., Ramkissoon, S. H., Alexander, B., Rinne, M. L., Colman, H., Omuro, A. M. P., DeAngelis, L. M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou209.20 · Cited by 10
Cited by
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis
Wang, J., Hu, K., Cai, X., Yang, B., He, Q., Wang, J., & Weng, Q. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.023 · Cited by 450
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
Costa, R. L. B., Han, H. S., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4697-y · Cited by 439
Lipid metabolism in cancer progression and therapeutic strategies
Fu, Y., Zou, T., Shen, X., Nelson, P. J., Li, J., Wu, C., Yang, J., Zheng, Y., Bruns, C., Zhao, Y., et al. (2021) · MedComm · doi:10.1002/mco2.27 · Cited by 393
Metadata
- Authors
- LoRusso, P. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-11-01
- Volume
- 34
- Issue
- 31
- Pages
- 3803-3815
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2518718875
- Cited by
- 470
- References
- 130
- FWCI
- 15.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.